Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Vistagen
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
April 25, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
April 09, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
April 01, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at Stifel 2024 Virtual CNS Days
March 11, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
February 28, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
February 13, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
February 06, 2024
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
December 27, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
November 09, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at Stifel 2023 Healthcare Conference
November 08, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences
November 07, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023
November 06, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
October 05, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
September 12, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan
September 05, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Appoints Cindy Anderson as Chief Financial Officer
August 22, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results
August 10, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023
August 08, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder
August 07, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray’s Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain
July 17, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease
July 13, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results
June 28, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023
June 27, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Regains Full Compliance with Nasdaq Listing Requirements
June 23, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder
June 21, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Participate in the Maxim Group Healthcare Virtual Conference Hosted by M-Vest
June 16, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine
June 13, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes
June 07, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen to Present at Jefferies 2023 Global Healthcare Conference
June 06, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Vistagen Announces Stockholder-Approved Reverse Stock Split
June 06, 2023
From
Vistagen
Via
Business Wire
Tickers
VTGN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.